Retisert FDA Approval History
FDA Approved: Yes (First approved April 8, 2005)
Brand name: Retisert
Generic name: fluocinolone acetonide
Dosage form: Intravitreal Implant
Company: Bausch & Lomb
Treatment for: Uveitis
Retisert (fluocinolone acetonide) intravitreal implant is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Development Timeline for Retisert
|Apr 8, 2005||Retisert Bausch & Lomb - Treatment for Chronic Non-Infectious Uveitis|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.